GPT Healthcare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
+16.1%+1.7%
+1.0%−5.1%
−11.2%−7.9%
−15.4%+4.5%
−15.3%+2.0%
+20.9%+11.2%
+8.7%+13.4%
+20.4%−2.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GPTHEALTH₹136.89

GPT Healthcare Limited

· Pharma & Health
₹ CrorePeersGKSLSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,123 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+1.7+16.1—
EBITDA Growth—-5.1+1.0—
EBIT Growth—-7.9-11.2—
Net Income Growth—+4.5-15.4—
EPS Growth—+2.0-15.3—
Total Assets Growth—+11.2+20.9—
Total Equity Growth—+13.4+8.7—
Cash from Operations Growth—-2.0+20.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.